Related Experiment Video

Updated: Apr 19, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.6K

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections

Christian Eckmann1, Joseph Solomkin

  • 1Klinikum Peine, Academic Hospital of Medical University Hannover, Department of General, Visceral and Thoracic Surgery , Virchowstrasse 8h, D-31221, Peine , Germany +49 0 5171 931530 ; +49 0 5171 931549 ; christian.eckmann@klinikum-peine.de.

Expert Opinion on Pharmacotherapy
|December 23, 2014
PubMed
Abstract

Insights

Ceftolozane/tazobactam offers an effective treatment for complicated intra-abdominal infections (cIAIs), including those caused by resistant bacteria like extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multidrug-resistant Pseudomonas aeruginosa.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Antimicrobial Resistance

Background:

  • Complicated intra-abdominal infections (cIAIs) present treatment challenges due to rising antimicrobial resistance.
  • Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas aeruginosa are significant pathogens in cIAIs.
  • Ceftolozane/tazobactam is a novel antimicrobial agent developed to address these challenges.

Purpose of the Study:

  • To review the mechanism of action, in vitro activity, and pharmacokinetic/pharmacodynamic properties of ceftolozane/tazobactam.
  • To discuss the clinical efficacy and safety of ceftolozane/tazobactam plus metronidazole in treating cIAIs.
  • To evaluate ceftolozane/tazobactam as a carbapenem-sparing option for MDR Gram-negative bacterial infections.

Main Methods:

  • Review of scientific literature on ceftolozane/tazobactam.
  • Analysis of in vitro data against common cIAI pathogens.
  • Examination of Phase II and III clinical trial data for efficacy and safety in hospitalized adults with cIAI.

Main Results:

  • Ceftolozane/tazobactam demonstrates potent in vitro activity against key cIAI pathogens.
  • Phase II and III trials show high clinical cure rates for ceftolozane/tazobactam plus metronidazole in cIAI patients.
  • The agent is effective in patients with infections caused by ESBL-producing Enterobacteriaceae and P. aeruginosa.

Conclusions:

  • Ceftolozane/tazobactam is an effective and safe treatment option for cIAIs.
  • It provides a valuable therapeutic choice for infections involving ESBL-producing Enterobacteriaceae and MDR P. aeruginosa.
  • Ceftolozane/tazobactam represents an important carbapenem-sparing alternative, aiding antimicrobial stewardship efforts against MDR Gram-negative bacteria.
Keywords:
Gram-negative bacteriaceftolozane/tazobactamcomplicated intra-abdominal infectionenterobacteriaceaemultidrug resistance

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R2029106:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.5K

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
763
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
635
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
413
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
94
Urinary Tract Infection I: Introduction01:26

Urinary Tract Infection I: Introduction

Urinary tract infections (UTIs) impact various parts of the urinary system, including the kidneys, ureters, bladder, and urethra. These infections are generally bacterial, with Escherichia coli being the most common causative agent, often originating from the gastrointestinal tract. However, other bacteria, such as Staphylococcus saprophyticus, Klebsiella pneumoniae, and Proteus mirabilis, are also known to cause UTIs. The type, location, and underlying complexity of the UTI guide both...
1.3K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
943